AbbVie and its subsidiaries have paid more than $7.5 billion in penalties and settlements since 2000, and the company is currently entangled in a wide slate of AbbVie lawsuits covering opioid marketing, Medicare drug price negotiation, the 340B discount program, trade secret theft in cancer drug development, antitrust claims around Humira and AndroGel, consumer pricing challenges, and shareholder suits.1Violation Tracker. AbbVie Parent Company Summary Some of the biggest cases are behind the company. Others are only now reaching the courts.
The $2.37 Billion Opioid Settlement
The largest single liability on AbbVie’s books comes from its subsidiary Allergan. In July 2022, Allergan agreed to pay up to $2.37 billion to resolve claims from a coalition of state attorneys general and local governments over the deceptive marketing of opioid painkillers.2Reuters. AbbVie To Pay Up to $2.37 Billion To Settle U.S. Opioid Claims The states alleged Allergan — which made the branded opioids Norco and Kadian along with generics — played down addiction risks, oversold benefits, pushed doctors to escalate doses in patients already showing signs of addiction, and failed to maintain controls against diversion.3Office of Attorney General, State of California. Attorney General Bonta Announces $2.37 Billion Nationwide Settlement With Former Opioid Manufacturer Allergan
AbbVie acquired Allergan in a $63 billion deal that closed in 2020. Allergan had already sold its generics business, including opioids, to Teva in 2016. Under the settlement, Allergan pays annually from 2023 through 2029, with roughly $2.15 billion going to opioid abatement after adjustments for prior state deals and attorney fees.4National Opioid Settlement. Allergan Public Global Opioid Settlement Agreement
The Botox Medicare Price Negotiation Challenge
On February 11, 2026, AbbVie sued the U.S. Department of Health and Human Services in the District of Columbia over Botox’s inclusion in Medicare’s drug price negotiation program.5Reuters. AbbVie Sues US Health Agency Over Botox Price Controls CMS had selected Botox for negotiated price cuts on January 27, 2026, with the lower price scheduled to take effect in 2028.6Fierce Pharma. AbbVie Mounts Fresh IRA Legal Challenge Over Botox’s Inclusion in Latest Drug Pricing
AbbVie’s argument is narrower than the sweeping constitutional attacks other drugmakers have brought. The company says Botox qualifies as a “plasma-derived product” because roughly one-third of the drug is human serum albumin, a protein extracted from human blood plasma, and that the Inflation Reduction Act expressly excludes plasma-derived biologicals from negotiation. Botox has contained the same three ingredients since its 1989 FDA approval, and the prescribing information describes albumin as “a derivative of human blood.” The suit also raises Takings, Due Process, First Amendment, and Administrative Procedure Act claims, and alleges that CMS never explained why it rejected the plasma-derived exception despite repeated outreach from the company.7Georgetown Law Litigation Tracker. AbbVie Inc. v. U.S. Department of Health and Human Services, Complaint
The money at stake is large. AbbVie reported nearly $3.8 billion in global Botox therapeutic sales in 2025 and another $2.6 billion in cosmetic sales.6Fierce Pharma. AbbVie Mounts Fresh IRA Legal Challenge Over Botox’s Inclusion in Latest Drug Pricing The case is before Judge Carl Nichols; AbbVie filed for summary judgment in April 2026.8Georgetown Law Litigation Tracker. AbbVie Inc. v. Department of Health and Human Services
The 340B Drug Discount Lawsuit
On April 8, 2026, AbbVie filed a second suit against the federal government, this one over the 340B drug discount program.9Georgetown Law Litigation Tracker. AbbVie Inc. v. Kennedy 340B requires manufacturers to sell certain outpatient drugs at reduced prices to safety-net providers like community health centers and public hospitals. AbbVie argues that the Health Resources and Services Administration’s definition of who counts as a “patient” is too broad and inconsistent with the 340B statute, letting covered entities claim discounts based on minimal or unrelated patient contact.10AbbVie. AbbVie Moves To Close Loopholes and Strengthen Accountability in 340B Program
The company wants the court to require that a qualifying prescription be tied to care at the facility, that the patient received substantive treatment, and that the provider has seen the patient within the past 12 months for the relevant condition.10AbbVie. AbbVie Moves To Close Loopholes and Strengthen Accountability in 340B Program The dispute is not new. In February 2022 AbbVie began restricting 340B pricing when providers used contract pharmacies; HRSA responded in October 2022 with a formal letter calling the restrictions illegal and demanding a plan to resume unrestricted sales.11340B Report. HRSA Tells AbbVie and Amgen Their 340B Contract Pharmacy Restrictions Are Illegal
The Genmab Trade Secret Fight
In March 2025, AbbVie sued Genmab, ProfoundBio, and two former AbbVie scientists in the Western District of Washington for trade secret misappropriation.12Genmab. Genmab Will Vigorously Defend Against Alleged Claims of Trade Secret The case involves antibody-drug conjugate technology, an increasingly important class of targeted cancer therapies. AbbVie alleges that former employee Tae Han co-founded ProfoundBio and then recruited another former AbbVie scientist, Julia Gavrilyuk, to supply proprietary knowledge about using open-chain sugars (specifically sorbitol) in ADC drug linkers to improve water solubility.13Fierce Biotech. AbbVie Takes Genmab to Court, Accusing Its Partner of Being Willfully Blind to ADC Trade Secret Theft
Genmab bought ProfoundBio in May 2024 for $1.8 billion. AbbVie says Genmab was “intentionally and willfully blind” to the technology’s origins and points to Genmab’s own due diligence notes flagging the “heavy use of sorbitol” in the linker platform.13Fierce Biotech. AbbVie Takes Genmab to Court, Accusing Its Partner of Being Willfully Blind to ADC Trade Secret Theft The technology appears in rinatabart sesutecan, a clinical-stage drug that would compete with AbbVie’s ADC Elahere.12Genmab. Genmab Will Vigorously Defend Against Alleged Claims of Trade Secret
Genmab denies the allegations, notes that AbbVie never commercialized the technology or sought a patent on it, and characterizes the suit as one of several AbbVie has filed against competitors involving former employees. Genmab also said the fight will not disrupt its existing collaboration with AbbVie on the cancer drug epcoritamab.14Labiotech. AbbVie Genmab Lawsuit The district court case has been stayed since January 2026 pending a parallel U.S. International Trade Commission investigation that AbbVie and partner ImmunoGen filed in late 2025, seeking to block importation of the allegedly infringing ADC products.15USITC. USITC Institutes Section 337 Investigation Regarding Certain Antibody Drug Conjugates
Humira: Patent Thicket Antitrust and Overpricing Class Action
Humira was for years the world’s best-selling drug, and AbbVie built more than 100 patents around it. A group of plaintiffs led by UFCW Local 1500 Welfare Fund sued, alleging the patent strategy and a set of “reverse payment” settlements with biosimilar developers including Amgen, Samsung Bioepis, Sandoz, and Fresenius Kabi had unlawfully kept cheaper versions out of the U.S. market.16Big Molecule Watch. The Seventh Circuit Affirms Dismissal of the Humira Antitrust Litigation
In August 2022 the Seventh Circuit affirmed dismissal. The court held that acquiring many patents is not by itself an antitrust violation, and because plaintiffs never alleged the patents were invalid or obtained by fraud, AbbVie was protected under the Noerr-Pennington doctrine. The court also found no illegal reverse payment in the structure of the biosimilar settlements, which allowed earlier entry in Europe than in the United States, because each regional deal reflected different patent rights.16Big Molecule Watch. The Seventh Circuit Affirms Dismissal of the Humira Antitrust Litigation
A separate consumer class action, filed in April 2023 in the Northern District of Illinois by Edward Camargo, accused AbbVie of inflating Humira’s list price by 470% over two decades while quietly offering much lower net prices to pharmacy benefit managers like CVS Health, Express Scripts, and Optum Rx. The claim was that this gap kept Humira on preferred formularies while consumers paid inflated co-insurance.17Hagens Berman. Class Action Accuses AbbVie Inc. of Unfair Pricing of Autoimmune Drug Humira Following 470% Cost Increase In January 2026 the court dismissed every count. The judge ruled that federal patent law impliedly preempts consumer claims attacking “excessive” prices on a patented drug, and dismissed the state consumer protection claims under Illinois, California, and Connecticut law for failure to plead damages, lack of extraterritorial reach, and statute of limitations problems. The dismissal was without prejudice, with an amendment deadline in February 2026.18Drug and Device Law Blog. No Harm, No Foul: Medicine Consumers Got What They Paid For
Rinvoq Generic Settlements and Shareholder Suit
AbbVie resolved patent litigation over its immunology drug Rinvoq (upadacitinib) by settling with every generic manufacturer that had sought FDA approval of a copycat. The deals, disclosed in a September 11, 2025, SEC filing, block generic upadacitinib from the U.S. market until April 2037, four years past the 2033 expiration of Rinvoq’s core composition patent.19Fierce Pharma. AbbVie Settles Generic Rinvoq Hopefuls, Shielding Immunology Blockbuster’s US Sales Until 2037 The settling manufacturers include Sandoz, Hetero Labs, Aurobindo Pharma, Intas Pharmaceuticals, and Sun Pharmaceuticals. Sandoz, in a related stipulation, admitted that its proposed generic infringed 23 AbbVie patents.20Generics Bulletin. Sandoz Admits to Widescale Infringement in Resolving US Rinvoq Patent Tussle
Rinvoq also triggered shareholder litigation. Investors alleged AbbVie executives made misleading statements in 2021 about Rinvoq’s safety relative to Pfizer’s Xeljanz, another JAK inhibitor. When the FDA announced JAK inhibitor safety warnings in September 2021 and later imposed new labeling requirements, AbbVie’s market cap fell by an estimated $15 billion and the company cut its 2025 Rinvoq revenue projection from $8 billion to $7.5 billion. The securities class action was voluntarily dismissed without prejudice in February 2023. The related shareholder derivative suit was dismissed in October 2024, with a federal judge in Illinois finding that plaintiffs had not adequately alleged the board could not fairly evaluate a pre-suit demand. That dismissal was also without prejudice.21Bloomberg Law. AbbVie Investors’ Suit Over Rinvoq Marketing Risks Dismissed
AndroGel Antitrust: FTC and Oregon
AbbVie’s longest-running antitrust case involved its testosterone replacement drug AndroGel. In 2014 the Federal Trade Commission sued AbbVie and co-defendant Besins Healthcare, alleging pay-for-delay settlements and sham patent litigation to block generic competition. The agency said AbbVie filed a baseless patent suit against generic maker Perrigo and entered an anticompetitive agreement with Teva that traded favorable terms on an unrelated drug, TriCor, for delayed generic AndroGel entry.22FTC. FTC v. AbbVie Inc., Case 121-0028
A federal judge in Philadelphia found AbbVie liable for monopolization through sham litigation and ordered $448 million in disgorgement in 2018. In September 2020 the Third Circuit upheld the sham-litigation finding but threw out the $448 million award, holding that disgorgement is not available under Section 13(b) of the FTC Act.23U.S. Court of Appeals for the Third Circuit. FTC v. AbbVie Inc., No. 18-2621 The Supreme Court’s separate ruling in AMG Capital Management v. FTC permanently foreclosed that remedy, and the FTC withdrew its remaining reverse-payment claims in July 2021. AbbVie and Teva remain under FTC orders restricting their ability to enter certain reverse-payment deals.22FTC. FTC v. AbbVie Inc., Case 121-0028
Oregon pursued its own case under state antitrust law. In February 2025, Attorney General Dan Rayfield announced a $9.25 million settlement with AbbVie and Besins over the same AndroGel conduct, including $6.2 million in disgorged profits and penalties. Oregon was the only state to recover profits from the scheme, with funds directed to the state Medicaid program and antitrust enforcement.24Oregon Department of Justice. AG Rayfield Secures $9,250,000 Settlement Against Pharmaceutical Giants AbbVie and Besins25KATU. Oregon Secures $9.25M Settlement Over Testosterone Gel Monopoly
Payer Matrix and the Humira Ambassador Program
AbbVie sued Payer Matrix in 2023, alleging that the company — which helps self-funded employer health plans cut specialty drug costs by steering patients into charitable assistance — was running a fraudulent scheme to exploit AbbVie’s patient assistance and co-pay card programs. After AbbVie changed its policy in January 2023 to exclude patients referred by alternative funding providers, Payer Matrix allegedly concealed its involvement by blocking identifying fax numbers and having patients submit applications directly. AbbVie also alleges Payer Matrix inflated patient cost-share obligations, pressured doctors to switch patients off AbbVie drugs, and sourced AbbVie-branded drugs from Canada. In April 2025 the court denied AbbVie’s request for a preliminary injunction, finding no irreparable harm after Payer Matrix’s CEO testified the company had stopped submitting AbbVie-related applications in mid-2023 and put internal blocks in place.26Justia. AbbVie Inc. v. Payer Matrix, LLC, Case No. 1:2023cv02836
On the receiving end, AbbVie paid $24 million in August 2020 to settle California Department of Insurance claims that its marketing of Humira violated the state’s Insurance Frauds Prevention Act. The case began as a whistleblower suit by a former nurse ambassador. California alleged AbbVie gave physicians kickbacks like meals and drinks to induce Humira prescriptions, and deployed nurse “Ambassadors” presented to patients as extensions of their doctors’ offices rather than AbbVie employees.27California Department of Insurance. Commissioner Lara Announces $24 Million AbbVie Settlement28STAT News. AbbVie, Humira, California Nurse Ambassadors Kickbacks The settlement required Ambassadors to disclose they work for AbbVie, barred sales reps from inviting prescribers to offsite business meals outside of speaker programs, and prohibited Ambassadors from joining patient-insurer conversations. AbbVie denied the allegations. A narrowed federal False Claims Act component of the same whistleblower case settled separately for $2.7 million in 2023.29California Department of Insurance. AbbVie Settlement Agreement30Schneider Wallace. AbbVie $2.7 Million Settlement False Claims Act Humira
The Running Total
Counting AbbVie and its subsidiaries and acquired companies, including Allergan, Forest Laboratories, and Abbott Laboratories, the corporate family has paid more than $7.5 billion in penalties across 85 tracked enforcement actions since 2000. Off-label or unapproved drug promotion is the largest category at roughly $5.4 billion, driven by the $2.37 billion opioid settlement and a $1.5 billion Abbott Laboratories settlement in 2012 over off-label marketing of Depakote. Competition-related penalties total about $1.65 billion, and False Claims Act cases add another $448 million.1Violation Tracker. AbbVie Parent Company Summary The pattern has shifted recently: alongside the state opioid payments running into 2024 and the Oregon AndroGel settlement in 2025, AbbVie is now the plaintiff in its biggest active fights, challenging federal drug pricing and discount programs rather than defending against enforcement.